While regulatory controls on methadone clinics for opioid dependence resulted in treatment being physically and functionally isolated from conventional medical care, the delivery of an office-based treatment of buprenorphine and the buprenorphine/naloxone combination product over the last decade has facilitated the return of treatment to “mainstream medicine both for psychiatry and primary care.” (Source: Psychiatric […]

Conclusion: Our findings suggest that illicit buprenorphine use is gaining ground primarily among whites and those who are more advanced in their drug use careers. Continued monitoring is needed to better understand evolving patterns and trends of illicit buprenorphine use. (Source: Drug and Alcohol Dependence) MedWorm Sponsor Message: Have a look at The Addiction Daily, […]

Updated Date: Jan 18, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)) MedWorm Sponsor Message: Find the best January Sales in the UK.

CONCLUSIONS  Office-based bup/nx for clinically stable patients may be a cost-effective alternative to no treatment at a threshold of $100,000/QALY depending on assumptions about quality-of-life weights. Additional research about quality-of-life benefits and broader health system and societal cost savings of bup/nx therapy is needed. Content Type Journal ArticleCategory Original ResearchPages 1-8DOI 10.1007/s11606-011-1962-8Authors Bruce R. Schackman, Department […]